101 related articles for article (PubMed ID: 29332135)
1. Sequential versus simultaneous use of chemotherapy and gonadotropin-releasing hormone agonist (GnRHa) among estrogen receptor (ER)-positive premenopausal breast cancer patients: effects on ovarian function, disease-free survival, and overall survival.
Zhang Y; Ji Y; Li J; Lei L; Wu S; Zuo W; Jia X; Wang Y; Mo M; Zhang N; Shen Z; Wu J; Shao Z; Liu G
Breast Cancer Res Treat; 2018 Apr; 168(3):679-686. PubMed ID: 29332135
[TBL] [Abstract][Full Text] [Related]
2. Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patient-Level Data.
Lambertini M; Moore HCF; Leonard RCF; Loibl S; Munster P; Bruzzone M; Boni L; Unger JM; Anderson RA; Mehta K; Minton S; Poggio F; Albain KS; Adamson DJA; Gerber B; Cripps A; Bertelli G; Seiler S; Ceppi M; Partridge AH; Del Mastro L
J Clin Oncol; 2018 Jul; 36(19):1981-1990. PubMed ID: 29718793
[TBL] [Abstract][Full Text] [Related]
3. Patient preferences and adherence to adjuvant GnRH analogs among premenopausal women with hormone receptor positive breast cancer.
Sukumar JS; Quiroga D; Kassem M; Grimm M; Shinde NV; Appiah L; Palettas M; Stephens J; Gatti-Mays ME; Pariser A; Cherian M; Stover DG; Williams N; Van Deusen J; Wesolowski R; Lustberg M; Ramaswamy B; Sardesai S
Breast Cancer Res Treat; 2021 Nov; 190(2):183-188. PubMed ID: 34498153
[TBL] [Abstract][Full Text] [Related]
4. Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT.
Regan MM; Walley BA; Francis PA; Fleming GF; Láng I; Gómez HL; Colleoni M; Tondini C; Pinotti G; Salim M; Spazzapan S; Parmar V; Ruhstaller T; Abdi EA; Gelber RD; Coates AS; Goldhirsch A; Pagani O
Ann Oncol; 2017 Sep; 28(9):2225-2232. PubMed ID: 28911092
[TBL] [Abstract][Full Text] [Related]
5. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy.
Moore HC; Unger JM; Phillips KA; Boyle F; Hitre E; Porter D; Francis PA; Goldstein LJ; Gomez HL; Vallejos CS; Partridge AH; Dakhil SR; Garcia AA; Gralow J; Lombard JM; Forbes JF; Martino S; Barlow WE; Fabian CJ; Minasian L; Meyskens FL; Gelber RD; Hortobagyi GN; Albain KS;
N Engl J Med; 2015 Mar; 372(10):923-32. PubMed ID: 25738668
[TBL] [Abstract][Full Text] [Related]
6. Gonadotropin-Releasing Hormone Agonists during Gonadal Chemotherapy for the Effect on Pregnancy Outcome and Ovarian Function in Premenopausal Patients with Breast Cancer: A Systematic Review and Meta-Analysis.
Yuan Y; Zhang C; Lei X; Ren T; Chen H; Zhao Q
Breast Care (Basel); 2023 Aug; 18(4):270-278. PubMed ID: 37900550
[TBL] [Abstract][Full Text] [Related]
7. Analysis of the benefit of gonadotropin-releasing hormone agonist treatment in premenopausal women undergoing hematopoietic cell transplantation.
Han R; Song Z; Li H; Wang C; Zhang L; Yang X
Sci Rep; 2023 Sep; 13(1):14497. PubMed ID: 37666835
[TBL] [Abstract][Full Text] [Related]
8. Adding Ovarian Suppression to Tamoxifen for Premenopausal Women With Hormone Receptor-Positive Breast Cancer After Chemotherapy: An 8-Year Follow-Up of the ASTRRA Trial.
Baek SY; Noh WC; Ahn SH; Kim HA; Ryu JM; Kim SI; Lee EG; Im SA; Jung Y; Park MH; Park KH; Kang SH; Jeong J; Park E; Kim SY; Lee MH; Kim LS; Lim W; Kim S; Kim HJ
J Clin Oncol; 2023 Nov; 41(31):4864-4871. PubMed ID: 37607321
[TBL] [Abstract][Full Text] [Related]
9. ProFertil study protocol for the investigation of gonadotropin-releasing hormone agonists (GnRHa) during chemotherapy aiming at fertility protection of young women and teenagers with cancer in Sweden-a phase III randomised double-blinded placebo-controlled study.
Rodriguez-Wallberg KA; Nilsson HP; Bergh J; Malmros J; Ljungman P; Foukakis T; Stragliotto CL; Friman EI; Linderholm B; Valachis A; Andersson A; Harrysson S; Vennström L; Frisk P; Mörse H; Eloranta S
BMJ Open; 2023 Dec; 13(12):e078023. PubMed ID: 38070906
[TBL] [Abstract][Full Text] [Related]
10. Impact of chemotherapy-induced amenorrhea in breast cancer patients: the evaluation of ovarian function by menstrual history and hormonal levels.
Meng K; Tian W; Zhou M; Chen H; Deng Y
World J Surg Oncol; 2013 May; 11():101. PubMed ID: 23688389
[TBL] [Abstract][Full Text] [Related]
11. Latent class joint model of ovarian function suppression and DFS for premenopausal breast cancer patients.
Zhang JJ; Wang M
Stat Med; 2010 Sep; 29(22):2310-24. PubMed ID: 20552577
[TBL] [Abstract][Full Text] [Related]
12. Different dosage forms of GnRHa with endocrine therapy in premenopausal hormone Receptor-Positive breast cancer.
Lin J; Ouyang Y; Li Y; Jin L; Li S; Liu Y; Yang Y; Shi Q; Zhu M; Cai Z; Wang J; Liu N; Hu Y; Wu Z; Wu M; Wong LL; Jiang X; Wang Q; Yang W; Liu Q
J Natl Cancer Inst; 2024 Jun; ():. PubMed ID: 38833681
[TBL] [Abstract][Full Text] [Related]
13. Preservation of gonadal function in women undergoing chemotherapy: a systematic review and meta-analysis of the potential role for gonadotropin-releasing hormone agonists.
Hickman LC; Llarena NC; Valentine LN; Liu X; Falcone T
J Assist Reprod Genet; 2018 Apr; 35(4):571-581. PubMed ID: 29470701
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant hormonal therapy in premenopausal women with operable breast cancer: not-so-peripheral perspectives.
Love RR
Oncology (Williston Park); 2010 Apr; 24(4):322-7. PubMed ID: 20464842
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of gonadotropin-releasing hormone agonists for ovarian function suppression in premenopausal patients with hormone receptor-positive breast cancer: a retrospective single-center real-world study.
Chen Y; Zhang R; Yan Y; Li H; Song G
Breast Cancer Res Treat; 2024 May; ():. PubMed ID: 38709374
[TBL] [Abstract][Full Text] [Related]
16. Expression profiles of E/P receptors and fibrosis in GnRHa-treated and -untreated women with different uterine leiomyomas.
Khan KN; Fujishita A; Koshiba A; Ogawa K; Mori T; Ogi H; Itoh K; Teramukai S; Kitawaki J
PLoS One; 2020; 15(11):e0242246. PubMed ID: 33186388
[TBL] [Abstract][Full Text] [Related]
17. Revisiting ovarian function suppression with GnRH agonists for premenopausal women with breast cancer: Who should use and the impact on survival outcomes.
Ma L; Yang B; Wu J
Cancer Treat Rev; 2024 May; 129():102770. PubMed ID: 38865794
[TBL] [Abstract][Full Text] [Related]
18. Decreased Level of Neurotrophic Factor Neuritin 1 in Women with Ovarian Endometriosis after Receiving Gonadotropin-Releasing Hormone Agonist Treatment.
Rahmawati E; Yang WV; Lei YP; Maurya PK; Chen HW; Tzeng CR
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31491902
[TBL] [Abstract][Full Text] [Related]
19. Survival outcome of combined GnRH agonist and tamoxifen is comparable to that of sequential adriamycin and cyclophosphamide chemotherapy plus tamoxifen in premenopausal patients with early breast cancer.
Sa-Nguanraksa D; Krisorakun T; Pongthong W; O-Charoenrat P
Mol Clin Oncol; 2019 Nov; 11(5):517-522. PubMed ID: 31620283
[TBL] [Abstract][Full Text] [Related]
20. Impact of Anti-Estrogen Therapy on Early Cardiovascular Referrals, Tests and Medications in Premenopausal Women with Operable Breast Cancer.
Douglas E; Levine B; Ansari A; Ansley K; Melin S; Park CJ; Richardson K; Hatcher S; D'Agostino RB; Jordan JH; Thomas A
Clin Breast Cancer; 2024 Jun; 24(4):e289-e296. PubMed ID: 38458842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
